Non-metastatic prostate cancer

Western Journal of Medicine

Volumn 171, Issue 2, 1999, Pages 97-101

  Wilt, Timothy J ^a   Brawer, Michael K ^b  

^a Northwest Prostate Institute   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347808937     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 995;154:2144-2148.
2. Landis SH, Murray T, Bolden S et al. Cancer statistics. CA Cancer J Clin 1998;48:6-29.
3. Whitmore WF. Localized prostatic cancer: management and detection issues. Lancet 1994;343:1263-1267.
4. Adolfsson J, Steineck G, Hedund P. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997;50:722-726.
5. Johansson J-E, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer: prospective, population-based study in Sweden. JAMA 1997;266:467-471.
6. Brawley OW. Prostate carcinoma incidence and patient mortality. Cancer 1997;80:1857-1863.
7. Wingo PA, Ries LAG, Rosenberg HM, et al. Cancer incidence and mortality, 1973-1995. Cancer 1998;82:1197-1207.
8. Fleming C, Wasson J, Albertsen PC, et al. A decision analysis of alternative strategies for clinically localized prostate cancer. JAMA 1993;269:2650-2658.
9. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-980.
10. Lu-Yao GL, Yao S. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-910.
11. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate: 23 year follow-up of a prospective randomized study. Scand J Urol Nephrol 1995;172(suppl):65-72.
12. Paulsen DF, Lin GH, Hinshaw W, et al. The uro-oncology group: radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502-504.
13. Lu-Yao GL, McLerran D, Wasson JH. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA 1993;269:2633-2636.
14. Screening for prostate cancer. Ann Intern Med 1997;126:480-484.
15. Fowler FJ, Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy: the national Medicare experience 1988-1990 (updated June 1993). Urology 1993;42:622-629.
16. Bishoff JT, Motley G, Optenberg SA, et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol 1998;160:454-458.
17. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129-135.
18. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial. Oncology 1997;11:1133-1139.
19. Norlen BJ. Swedish randomized trial of radical prostatectomy versus watchful waiting. Can J Oncol 1994;4(suppl 1):38-42.
20. Fowler FJ, Barry MJ, Lu-Yao G, et al. Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996;14:2258-2265.
21. Crook J, Perry G, Robertson S, Esche B. Routine prostate biopsies: results for 225 patients. Urology 1995;45:624-632.
22. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-459.
23. Health Care Financing Administration. Medicare claims data, calendar year 1995.
24. Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol 1991;137(Suppl):113.
25. Technology Evaluation Center. Relative effectiveness and cost-effectiveness of available methods of androgen suppression in the treatment of advanced prostate cancer. Chicago: Blue Cross Blue Shield Association. In press.
26. Byar DP, Corle DK. Hormone treatment for prostate cancer: results of the Veterans' Administration cooperative urologic research group studies. National Cancer Institute Monograph 1988;7:165-170.
27. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235-246.